We are Experienced
Drug Developers
At Pimera, we have an experienced team with a successful track record in drug development and company building. We have leveraged these skills to create a deep pipeline of programs advancing through the clinic with large market opportunities in cancer and other diseases with high unmet medical need.
Our Lead Program is PMR-116
PMR-116 is our lead therapeutic in clinical development for multiple cancer indications including solid tumors. PMR-116 acts through a novel mechanism of action, targeting the RNA polymerase I, or POL I, a transcription factor for MYC driven cancers and other diseases with high unmet medical need.
We are Always Discovering.
We are also working on several discovery-stage efforts where we understand the underlying disease biology and believe that we can identify a novel therapeutic approach.
Featured News
Pimera Therapeutics Announces Grant Award from Medical Research Future Fund (MRFF) for Expansion of Phase 1a/b Study of PMR-116 for MYC-driven Cancers
-Study will be run in Australia by the ANU and its collaborators in the ACT, New South Wales, and Victoria- San Diego, CA, June 18, 2025 -- Pimera ...
Pimera Therapeutics to Present at the January 2023 Biotech Showcase in San Francisco
SAN DIEGO, Dec. 7, 2022 /PRNewswire/ -- Pimera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing breakthrough medicines for cancer and other diseases with high unmet medical ...
Pimera Therapeutics Announces Oral Presentation on PMR-116 at the American Association for Cancer Research (AACR) Annual Meeting 2022
San Diego, CA, March 9, 2022 -- Pimera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing breakthrough medicines for cancer and other diseases with high unmet medical ...